Stocks for Exact Sciences leaped 33% after it announced the acquisition of liquid biopsy rival Thrive and UK start-up Base Genomics. Exact Sciences said it has agreed to buy Thrive for a cash and ...

Exact Sciences has a multipronged approach to cancer ... Despite its acquisitions of Base Genomics and Thrive for a combined total of $2.6 billion, which were announced in 2020, the company ...

Positive results of a colon cancer study conducted by Exact Sciences prompt the CEO of competitor Guardant Health to publicly challenge his rival to a bet. Exact’s test could compete with ...

Exact Sciences soared as much as 33% on Tuesday to record highs after the diagnostics company said it would acquire Thrive Earlier Detection for up to $2.15 billion in a stock and cash deal.

Analyst Tycho Peterson of Jefferies assigned a Buy rating on Exact Sciences (EXAS – Research Report), with a price target of $84.00.

Exact Sciences stock bounded higher Thursday after beating second-quarter expectations, signaling a return to growth for its biggest moneymaker, a colon cancer test called Cologuard. Please watch ...

Exact Sciences (EXAS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mark ...

Gardening in the summer can be a bit of a chore, especially when it comes to watering your plants. It's not just about how much water you give them, but also when you do it. Whether they're ...

Analysts also raised price targets for Applovin and Arm Holdings. Wall Street Analysts Believe Exact Sciences Could Rally 34.33%: Here's is How to Trade Exact Sciences (NASDAQ: EXAS) closed the ...

Investors with a lot of money to spend have taken a bullish stance on Exact Sciences EXAS. And retail traders should know. We noticed this today when the positions showed up on publicly available ...

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called ...